Navigation Links
Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer,Study Presented at ASCO

) (2-methoxyestradiol or 2ME2), the Company's lead drug candidate, is currently in multiple Phase 2 clinical trials for cancer, as well as in preclinical development for rheumatoid arthritis. MKC-1, an oral cell-cycle regulator, is in various Phase 2 studies for cancer. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's website at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical tria
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:8/28/2014)... 2014  Seres Health, a clinical-stage therapeutics company ... human microbiome, announced today that Dr. David ... and Chief Scientific Officer, will be presenting at ... Chemotherapy (ICAAC). The presentation will highlight the scientific ... of bacterial spores derived from the human microbiome, ...
(Date:8/28/2014)... 2014   Venaxis, Inc.  (Nasdaq:  APPY), an ... clearance for and commercializing its CE Marked APPY ... identifying children, adolescent, and young adult patients in the ... today announced it will present at three upcoming investor ... Global Investment Conference being held in New ...
(Date:8/28/2014)... PLYMOUTH MEETING, Pa. , Aug. 28, 2014 ... surgical community, patients, and media, both for the ... to patient safety. The quick deployment of surgical ... new technology are prompting facilities to evaluate their ... for the entire surgical team.    ...
Breaking Medicine Technology:Seres Health to Present Clinical Findings at ICAAC 2014 Conference 2Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5
... Delcath Systems, Inc. (Nasdaq: DCTH ) today ... of Directors. Dr. Contag is a proven corporate executive with ... , (LOGO: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ... Cobalt Technologies, Inc. in 2006 and served as CEO. Prior ...
... & Alzheimer,s Disease , , ... today announced that its researchers have uncovered a new ... a potential target for developing novel therapeutics for intervention ... Institute,s Pancham Bakshi, Ph.D., is detailed in the ...
Cached Medicine Technology:Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 2Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 3Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer's Disease 2Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer's Disease 3
(Date:8/28/2014)... 28, 2014 Testimony began this ... a transvaginal mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ )involving ... LLP reports. Court documents pending in the U.S. ... that the case was filed on behalf of ... surgeries, allegedly due to vaginal mesh complications associated ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 The Governor ... Microcredit Summit at a press conference; this event ... with the Ministry of Economy through the National Microenterprise ... from September 2nd to the 5th at the Convention ... , “It is a great responsibility for Yucatan to ...
(Date:8/28/2014)... Kirklyn Smith, an office manager for EzCOI.com , is ... by walking 5,000 miles in a single year without ever ... thousands of individual stories of TrekDesk treadmill desk users across ... than the others. , Kirklyn has launched a website that ... range of 54,823 steps (presumably on an off day) to ...
(Date:8/28/2014)... August 28, 2014 Bank lending to the ... year, down by 0.13% in real terms, and continuing to ... new study by UHY, the international accountancy network. , UHY ... businesses in particular, the credit crunch lingers on. , UHY ... the last year have been wiped out by inflation. Over ...
(Date:8/28/2014)... of sleep not only puts teens at risk for poor ... researchers warn. The study authors analyzed data collected from ... 21. Nearly one-fifth of them got less than six hours ... this group was 20 percent more likely to be obese ... hours of sleep per night at age 16, the investigators ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 2Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 3Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 3Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 4Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 5Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 6Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 7Health News:Less Sleep in Teen Years Tied to More Pounds at 21 2
... new study, a serious form of cancer that arises in ... normally serve as ‘scouts’ for the immune system. ... virus (EBV), which is usually kept under check by the ... control is lost and the transplanted organ may be rejected. ...
... characterized by pain and tenderness in the jaw muscles ... ,TMD is a problem for millions of Americans whose ... open-joint surgery. Whole system naturopathic care as a treatment ... of a new study involving 160 women in the ...
... a research conducted to study the link between work-related ... real or threatened violence at workplace run a major ... showed that the magnitude of the risk was in ... ,The findings of the study have been published ...
... of just a few puffs of cigarette that is capable ... that the amount of nicotine present in a single puff ... receptors and 3 puffs can occupy nearly 70% of these ... the receptors are filled up. But this feeling of satisfaction ...
... has now risen to 19 from 17. The official ... encephalitis was spreading rapidly.// ,Health officials in ... infections had emerged since July 13. Encephalitis causes the ... left untreated can be fatal. In China, health authorities ...
... The calories that contribute to ill health are loaded in ... consequentially off the lives of many // , who are ... with, the ideal thing would be to ensure the promotional ... that people are dished out the right information about healthy ...
Cached Medicine News:Health News:Deficient 'Scout Cells' Causes Cancer in Transplant Patients 2Health News:Deficient 'Scout Cells' Causes Cancer in Transplant Patients 3Health News:Naturopathic Care Proves Beneficial for TMD Pain 2Health News:Work-Related Violence Increases Risk Of Depression 2Health News:Imaging study affords renewed thrust on smoking cessation treatments 2Health News:Imaging study affords renewed thrust on smoking cessation treatments 3
Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption....
... Control is designed to ... significant range of those ... during fertility or pregnancy ... hCG-Beta Subunit levels allow ...
... provides the clinical laboratory with the ... for monitoring immunoassay and therapeutic drug ... separate controls. Made from human serum ... suitable for most methods and is ...
Lyphochek Immunology Plus Control is an assayed control for monitoring chemistry procedures that test for autoimmune, anemic, malignant, hepatic and nephrotic-disease states. Available in two levels....
Medicine Products: